This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hakeem, L. Articles by Bhattacharyya, D. N. Search for Related Content Social Bookmarking                         What's this?

HIV-associated lipodystrophy - a new metabolic syndrome

Infectious Diseases Unit, Victoria Hospital, Kirkcaldy, Fife, Scotland, lukman.hakeem{at}faht.scot.nhs.uk

Ian W Campbell

Diabetic Centre, Victoria Hospital, Kirkcaldy, Fife, Scotland

Diptendu Nath Bhattacharyya

Infectious Diseases Unit, Victoria Hospital, Kirkcaldy, Fife, Scotland

Human immunodeficiency virus (HIV) associated lipodystrophy may affect up to half or even more HIV-infected patients receiving antiretroviral therapy. However, a simple practical definition for this condition is still lacking. Features of lipoatrophy and lipohypertrophy may be seen in this condition. Intrinsic host factors and disease status, as well as treatment duration and type, probably play key roles in the aetiology. Several metabolic abnormalities such as dyslipidaemia and insulin resistance have been commonly reported in these patients. Most attempts to improve or reverse abnormal fat distribution have so far only shown modest success. Therefore, choosing optimal antiretroviral therapy is vital. There are too few reasons to support widespread use of rosiglitazone and metformin in these patients except on an individual basis. However, lipid lowering agents should be considered in the treatment of severe hypertriglyceridaemia and elevated low-density lipoprotein-cholesterol or a combination of both as lipid abnormalities are commonly seen in thesepatients. Advances in plastic surgery are attractive treatment options as they give immediate results.

Key Words: antiretroviral therapy • human immunodeficiency virus lipodystrophy • metabolic syndrome.

References

• Wierzbicki AS, Purdon SD, Hardman TC et al. Clinical aspects of the management of HIV Lipodystrophy. Br J Diabetes & Vasc Dis 2008;8:113-19.[Abstract/Free Full Text]
• Milinkovic A., Martinez E. Current perspectives on HIV-associated lipodystrophy syndrome. J Antimicrob Chemother 2005;56:6-9.[Abstract/Free Full Text]
• Carr A., Samaras K., Burton S. et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heath K., Hogg RS, Chan KJ et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Friis-Moller N., Weber R., Reiss P. et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wanke C. Editorial comment: a case definition for HIV lipodystrophy- a work in progress. AIDS Read 2003;13:492-3.[Medline] [Order article via Infotrieve]
• Carr A., Emery S., Law M., Puls R., Lundgren JD, Powderly WG HIV Lipodystrophy Case Definition Study Group. Lancet 2003;361:726-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Saint-Marc T., Partisani M., Poizot-Martin L. et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Enzi G., Gasparo M., Biondetti PR et al. Subcutaneous and visceral fat distribution according to sex, age and overweight, evaluated by computed tomography. Am J Clin Nutr 1986;44:739-46.[Abstract/Free Full Text]
• Asensi V., Martin-Roces E., Carton JA et al. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1 infected patients receiving highly active antiviral therapy. Clin Infect Dis 2004;39:240-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Martinez E., Bianchi L., Garcia MA et al. Sonographic assessment of regional fat in HIV infected persons. Lancet 2000;3 R 56:1412-13.
• Wanke CA Epidemiological and clinical aspects of metabolic complications of HIV infection: the fat redistribution syndrome. AIDS 1999;
• :1287-93. 13. Nolan D., Pace C. Potential roles for uncoupling proteins in HIV lipodystrophy. Mitochondrion 2004;4:185-191.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lichtenstein KA Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39:395-400.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sekhar RV, Jahoor F., Pownall HJ et al. Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolaemia in HIV lipodystrophy syndrome. Am J Clin Nutr 2005;81:1405-10.[Abstract/Free Full Text]
• Sekhar RV, Jahoor F., White AC et al. Metabolic basis of HIV lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002; 283:E332-E337.[Abstract/Free Full Text]
• Johnson JA, Albu JB, Engelson ES et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004;286:E261-E271.[Abstract/Free Full Text]
• Rietschel P., Hadigan C., Corcoran C. et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001;86:504-10.[Abstract/Free Full Text]
• Batterham M., Garsia R., Greenop P. et al. Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy. `Diet FRS Study'. AIDS 2000;14:1839-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Behrens G., Schmidt RE Lipodystrophy syndrome. HIV Medicine 2005; Chapter 7:283-98. www.HIVMedicine.com
• Shlay JC, Visnegarwala F., Bartsch G. et al. Body composition and metabolic changes in antiretroviral naïve patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005;38:147-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Martinez E., Arnaiz JA, Podzamcer D. et al. Substitution of Nevirapine, Efavirenz or Abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003;349:1036-46.[Abstract/Free Full Text]
• Carr A., Hudson J., Chau J. et al. HIV protease inhibitor substitution in patients with lipodystrophy: randomised, controlled, open-label, multi-centre study. AIDS 2001;15:1811-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Martin A., Smith DE, Ringland C. et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to Abacavir: the MITOX extension study. AIDS 2004;18:1029-36.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Moyle G., Sabin C., Cartledge J. et al. A 48-week, randomized, open-label comparative study of Tenofovir DF vs. Abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005. Abstract 44LB, p.81. Foundation for Retrovirology and Human Health, Alexandria VA, USA.
• Gelato MC, Mynarick DC, Quick JL et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with Rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002; 31:163-70.[Web of Science][Medline] [Order article via Infotrieve]
• Sutinen J., WHakkinen AM, Westerbacka J. et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized doubleblind placebo controlled study. Antivir Ther 2003;8:199-207.[Medline] [Order article via Infotrieve]
• Carr A., Workman C., Carey D. et al. No effect of Rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004;363:429-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mallon P., Sedwell GT, Rogers G. et al. The effect of Rosiglitazone on PPAR- expression in human adipose tissue is limited by continued exposure to thymidine NRTI. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Human Health, Alexandria, VA, USA.
• Schambelan M., Benson C., Carr A. et al. Management of metabolic complications associated with antiviral therapy for HIV-infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2003;31:257-75.[Web of Science]
• Kotler DP, Muurahainen N., Grunfeld C. et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidaemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004;34:239-52.
• Rao A., D'Amico S., Balasubramanyam A. et al. Fenofibrate is effective in treating hypertriglyceridaemia associated with HIV lipodystrophy. Am J Med Sci 2004;327:315-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Badiou S., Merle De Boever C., Dupuy AM et al. Fenofibrate improves the atherogenic lipid prophile and enhances LDL resistance to oxidation in HIV positive adults. Atherosclerosis 2004;172:272-9.
• Miller J., Brown D., Amin J. et al. A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002;16:2195-200.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ponce-De-Leon S., Iglesias M., Ceballos J. et al. Liposuction for protease inhibitor associated lipodystrophy. Lancet 1999;353:1244.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wolfort FG, Cetrulo CL, Nevarre DR Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV protease inhibitor use. Plast Reconstr Surg 1999;104:1814-20.[Web of Science][Medline] [Order article via Infotrieve]
• Fontdevilla J., Milinkovic A., Martinez E. et al. Treatment of facial lipoatrophy by injection of autologous adipose tissue. Antivir Ther 2003; 8:L76.
• Serra-Renom JM, Fontdevila J. Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. Plast Reconstr Surg 2004;114:551-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 3, 129-134 (2008)
DOI: 10.1177/14746514080080030401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. S Wierzbicki, S. D Purdon, T. C Hardman, R. Kulasegaram, and B. S Peters Review: Clinical aspects of the management of HIV lipodystrophy The British Journal of Diabetes & Vascular Disease, May 1, 2008; 8(3): 113 - 119. [Abstract] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hakeem, L. Articles by Bhattacharyya, D. N. Search for Related Content Social Bookmarking                         What's this?